Literature DB >> 14670538

Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi.

Paul Sweeney1, Christopher G Wood, Louis L Pisters, Joel W Slaton, Ara Vaporciyan, Mark Munsell, Scott Carpenter, Joe Putnam, Stephen G Swisher, Garret Walsh, David Swanson, Colin P N Dinney.   

Abstract

The operative morbidity and mortality of radical nephrectomy are considerably higher when the vena cava is involved by the tumor. The prognostic significance of vena caval extension in this setting remains controversial. We reviewed our experience of vena caval thrombectomy specifically addressing prognostic factors. We retrospectively studied 96 patients treated at our institution between 1985 and 2001. The study population included 28 women and 68 men; (37 left- and 59 right-sided tumors). Twenty-seven patients had metastatic disease at presentation. Prognostic features (age, sex, race, side of tumor, embolization, tumor grade, tumor confinement by renal capsule, cephalic extent of thrombus, nodal status, and presence of distant metastasis) were evaluated using a Cox proportional hazards model (univariate and multivariate). These prognostic features were analyzed in the group as a whole and in the subgroup of patients who did not have metastatic disease at presentation and did not die perioperatively. There were 5 perioperative deaths. Extracapsular tumor extension and regional node involvement were present in 64% and 17% of the patients, respectively. Level of tumor thrombus were as follows: level I (41%), II (29%), III (7%), IV (15%). Fuhrman's grade was 2 in 17%, 3 in 45%, and 4 in 30% of the patients. For all 96 patients, median overall survival (OS) was 35 months. Five-year OS was 35%. The presence of distant metastasis at presentation did not significantly alter median OS (20 months with metastasis vs. 38 months without, P = 0.3), although this finding may have been confounded by selection. The presence of nodal metastasis was associated with decreased OS by multivariate analysis (P < 0.01). After exclusion of patients dying perioperatively and patients with metastasis at presentation, median OS and progression-free survival were 40 and 18 months, respectively (5-year OS was 40%). In the multivariate model, none of the factors examined were associated with OS, but age <58 years, and the presence of extracapsular tumor extension were associated with an increased risk of recurrence. In patients with renal tumors and extension of tumor thrombus into the vena cava, the level of propagation of the thrombus does not predict for OS. Selected patients with metastatic renal cancer may benefit from aggressive surgical resection of the primary tumor and associated tumor thrombus.

Entities:  

Mesh:

Year:  2003        PMID: 14670538     DOI: 10.1016/s1078-1439(02)00280-6

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  20 in total

Review 1.  Update on surgical management of renal cell carcinoma with venous extension.

Authors:  Javier González
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Single-Centre Experience of Supra-Renal Vena Cava Resection and Reconstruction.

Authors:  Nikola Vladov; Radoslav Kostadinov; Vassil Mihaylov; Ivelin Takorov; Tsonka Lukanova; Maria Yakova; Tsvetan Trichkov; Evelina Odisseeva; Ventsislav Mutafchiyski
Journal:  World J Surg       Date:  2021-03-16       Impact factor: 3.352

3.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

4.  Surgical resection of recurrent inferior vena cava tumor following radical nephrectomy for renal cell carcinoma: A case report.

Authors:  Guangyuan Li; Zhiqiang Zhang; Dongdong Xie; Nan Ye; Dexin Yu
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

5.  Renal tumor with tumor thrombus in inferior vena cava and right atrium: the report of five cases with long-term follow-up.

Authors:  Djordje Radak; Predrag Milojevic; Srdjan Babic; Predrag Matic; Slobodan Tanaskovic; Vinka Vukotic; Tomislav Pejcic; Jovan Hadzi-Djokic
Journal:  Int Urol Nephrol       Date:  2011-03-27       Impact factor: 2.370

6.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

7.  Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Authors:  Christian Niedworok; Bettina Dörrenhaus; Frank Vom Dorp; Jarowit Adam Piotrowski; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Marcus Schenck
Journal:  World J Urol       Date:  2014-11-30       Impact factor: 4.226

Review 8.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

9.  Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness.

Authors:  Giueng-Chueng Wang; Po-Shiuan Hsieh; Hsian-He Hsu; Guang-Huan Sun; Shin Nieh; Cheng-Ping Yu; Jong-Shiaw Jin
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

10.  Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer.

Authors:  Beste Ozben; Nurdan Papila; M Azra Tanrikulu; Fatih Bayalan; Ali Serdar Fak; Ahmet Oktay
Journal:  J Thromb Thrombolysis       Date:  2007-05-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.